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Summary S9788 is a new triazineaminopiperidine derivate capable of reversing multidrug resistance (MDR) in cells resistant to
chemotherapeutic agents such as doxorubicin. It does not belong to a known class of MDR revertants, but its action involves the binding of
P-glycoprotein. Thirty-eight evaluable patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone (16 patients)
followed after disease progression with combination treatment of doxorubicin plus S9788 (12 patients) or upfront with the combination of
doxorubicin plus S9788 (22 patients). S9788 was given i.v. as a loading dose of 56 mg m-2 over 30 min followed by doxorubicin given at
50 mg m-2 as a bolus infusion. Thereafter, a 2-h infusion of S9788 was administered at escalating doses ranging from 24 to 120 mg m-2 in
subsequent cohorts of 4-10 patients. Pharmacokinetic analysis demonstrated that concentrations of S9788 that are known to reverse MDR
in vitro were achieved in patients at non-toxic doses. Compared with treatment with doxorubicin alone, treatment with the combination of
doxorubicin and S9788 produced a significant increase in the occurrence of WHO grade 3-4 granulocytopenia. Treatment with S9788 was
cardiotoxic as it caused a dose-dependent and reversible increase in corrected QT intervals as well as clinically non-significant arrhythmias
on 24- or 48-h Holter recordings. Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of
S9788 may increase the risk of severe cardiac arrhythmias. Twenty-nine patients treated with S9788 plus doxorubicin were evaluable for
response, and one patient, who progressed after treatment with doxorubicin alone, achieved a partial response. We conclude that S9788
administered at the doses and schedule used in this study results
administered in combination with doxorubicin.
Inherent or acquired multidrug resistance (MDR) is an important
cause of failure of cancer chemotherapy. Several mechanisms
responsible for MDR have been described, and the most exten-
sively investigated is the expression of the product of the MDRJ
gene, P-glycoprotein (P-gp) or P-170 (Roninson, 1992). This
protein acts as an efflux pump for a number of commonly used
cytotoxic agents, e.g. doxorubicin, vincristine, vinblastine and
actinomycin D. Different compounds have been shown to reverse
P-gp-mediated MDR, including calcium channel antagonists
(verapamil), calmodulin inhibitors (quinine, quinidine), oestrogen
receptor antagonists (tamoxifen), steroids and immunomodulators
(cyclosporin A). The mechanisms by which these drugs influence
MDR have not always been identified. The clinical use of these
MDR modulators is hampered by the toxic side-effects that occur
when the suprapharmacological doses required to achieve signifi-
cant reversal of MDR are used (Pennock et al, 1991; Raderer and
Scheithauer, 1993). Therefore, the search for novel and more
potent MDR modulators is ofmajor importance.
S9788 is a triazineaminopiperidine derivate capable ofreversing
MDR in vitro andin vivo in adose-dependent way (Cros et al, 1992;
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in relevant plasma concentrations in humans and can safely be
Pierre et al, 1992). Structurally, S9788 does not belong to any of
the classes ofcompounds known to reverse MDR. It increases the
intracellular accumulation and retention of doxorubicin,
vincristine and vinblastine in resistant cell lines displaying the P-
gp-mediated MDR phenotype (Leonce et al, 1992; Efferth
et al, 1993; Hill et al, 1993; Huet et al, 1993; Julia et al, 1994;
Merlin et al 1994). These studies also showed that modulation of
resistance is obtained in both drug-selected and inherently resis-
tant cell lines, and that S9788 is more potent than verapamil at
equimolar concentrations. It has been hypothesized that, in addi-
tion to P-gp binding, S9788 may also act by altering the intracel-
lular drug distribution (Merlin et al, 1994; Sebille et al, 1994).
Although the optimum schedule has not yet been defined, a
prolonged infusion of S9788 starting before and maintained after
the administration of chemotherapy appears to be more effective
than a single-bolus infusion (Perez et al, 1993; Julia et al, 1994;
Soudon et al, 1995). S9788 has been shown not to interfere with
doxorubicin plasma pharmacokinetics (de Valeriola et al, 1997).
Preliminary results of phase I studies of doxorubicin plus S9788,
the latter being infused over 30 min or 6 h, have shown cardiac
arrhythmias (mainly AV blocks, bradycardia, tachycardia),
hypotension and prolongation of the QT interval on electrocar-
diograms in some patients (Awada et al, 1993; Clavel et al, 1993;
Goncalves et al, 1995). Most of these cardiac toxicities were
asymptomatic. This prompted us to keep patients under close
cardiac surveillance in the present study. Only patients with
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advanced colorectal and renal cell cancer were included in the
study as these types of cancer are resistant to anthracyclins, with
response rates of 7% (95% CI 1.9-17%) and 2.9% (95% CI
1.8-4.2%) respectively (Frytak et al, 1975; Yagoda et al, 1995).
Although other mechanisms may play a role in their resistance
to chemotherapy (Redmond et al, 1991; Chapman and Goldstein,
1995), tumour cells of both these types of cancer are known to
express the MDR] gene and contain high levels of P-gp activity
(Goldstein et al, 1989; Kanamaru et al, 1989; Lai et al, 1991;
Kramer et al, 1993), and this may therefore play a key role in their
resistance to anthracyclins. The aims of the present study were to
investigate the toxicity, anti-tumour activity and pharmacokinetics
of S9788 administered before and after infusion of doxorubicin
in patients with advanced colorectal and renal cell cancer. A
suboptimal dose of doxorubicin was chosen for this study
(50 mg M-2 once every 3 weeks) because of the possible
potentiation ofits side-effects by S9788.
MATERIALS AND METHODS
Inclusion criteria
Eligibility criteria includedhistological proofofadvancedcolorectal
or renal cell cancer with documented progression within the last 2
months before entry into the study, measurable disease parameters,
age between 18 and 75 years, Karnofsky performance status >80%,
no radiotherapy, hormone therapy orimmunotherapy during the last
2 weeks and no chemotherapy during the last 4 weeks before study
entry. Normal values for Hb, platelets, WBC and serum electrolytes
were required. Liver transaminases were allowed to be S 2.5 times
and bilirubin, amylase, creatinine and urea < 1.25 times the upper
normal values, and creatinine clearance .60 ml min-'. Any history
ofsignificant cardiac arrhythmias, cardiac failure or recent myocar-
dial infarction was not allowed, and patients were required to have
normal cardiac ventricular ejection fraction (240%), no clinical
signs of central nervous system metastasis, no concurrent use of
other investigational or anti-neoplastic agents and no second malig-
nancy. Written informed consent was obtained from all patients.
Before initiation ofthis trial, institutional review board approval was
obtained at each ofthe participating centres.
Study design and drug administration
Patients wereeitherinitially treated with the combination ofdoxoru-
bicin and S9788, or after documented progression of disease on
treatment with doxorubicin alone. This decision was left to the
investigators of the various institutions, as some centres considered
treatment of patients with colorectal and renal cell cancer with
single-agent doxorubicin not acceptable. S9788 (6-4-[2,2-di(4-fluo-
rophenyl) ethylamino] 1-piperidinyl] N,N'-di,2-propenyl 1,3,5-
triazine 2,4-diamine) was provided by IRIS (Courbevoie, France)
in 10-ml vials at a concentration of 10 mg ml-' formulated in a
bismethane sulphonate salt solution. The drug was diluted in either
250 ml (loading dose) or 1000 ml (2-h infusion) of dextrose 5% in
water. A fixed loading dose of S9788 at 56 mg m-2 administered
over 30 min i.v. was followed by a 2-h infusion at different dose
levels starting at 24 mg m-2. Doxorubicin 50 mg m-2 was adminis-
tered over 5 min i.v. either alone ordirectly afterthe loading dose. A
minimum of three patients were entered at each 2-h infusion dose
level ofS9788. Nointra-patient dose escalation was allowed. Cycles
were repeated every 3 weeks. All patients received antiemetic
prophylaxis before doxorubicin infusion. Dose-limiting toxicity
(DLT) was defined as any of the following events: (1) decrease >
15% ofventricular ejection fraction; or (2) mucositis, cardiac, renal,
hepatic, neurological or any major unexpected toxicity 2 WHO
grade 3. DLT occurring in two or more patients treated at the same
dose level was considered as the clinical end point for this study.
Study monitoring
A complete history, physical examination, performance status and
laboratory studies [complete blood cell count with leucocyte differ-
ential (weekly), prothrombin and partial thromboplastin times,
blood urea nitrogen, serum electrolytes, creatinine, calcium, phos-
phorus, liver transaminases, total bilirubin, amylase, alkaline phos-
phatase and urinalysis] were obtained at baseline and before each
cycle. Ventricularejection fraction, determinedby eitherultrasound
or nuclear scanning, was planned for each patient at baseline and
after completion of every two cycles. It was intended that all
patients should have continuous cardiac telemetry and/or Holter
recording for 24 h starting a minimum of 30 min before S9788
infusion or doxorubicin alone. Determination of the maximum
corrected QT intervals (QTc max) was performed according to the
method described by Bazett (1920). QTc values of .440 ms
were considered as normal. Twelve-lead electrocardiograms were
performed before and directly after each cycle. Patients were evalu-
ated weekly fortoxicity and every two cycles forresponse. Toxicity
and response were scored according to WHO criteria. Cycles could
only be repeated if granulocyte cell counts were 2 2000 x 106 1-'
and in the absence ofgrade 2 2 mucositis, renal, hepatic, neurolog-
ical or other haematological toxicity atthe time ofretreatment.
Pharmacokinetic analysis
Heparinized venous blood samples were collected before and at the
end ofthe 30-min infusion ofthe loading dose ofS9788 as well as
before and 1 h, 2 h, 2.5 h and 24 h after the start ofthe 2-h mainte-
nance infusion of S9788. Samples were quickly centrifuged and
plasma was stored at -20°C until analysis. S9788 was quantitated
by a specific high-performance liquid chromatographic method
(HPLC) as described previously (Bakes et al, 1993) using a solid-
phase extraction procedure and a reversed-phase HPLC (Hypersil
ODS) with ultraviolet detection (230 nm). The mean precision and
accuracy were 5.0% and 7.9%, respectively, over a range of 1-
500 ng ml-' with a quantification limit of 1 ng ml-'. S9788 plasma
concentrations were modelled over time, using extended least
squares regression on thecomputerprogramMicropharm (S. Vrien,
LOGINSERM) version 4.0. The two-compartment model was
chosen using Akaike's information criterion (Yamaoka et al, 1978).
The total body clearance (Cl, h 1-1), distribution volume at steady
state (Vdss, I), distribution half-life (t'%2a, min) and elimination
half-life (t'/213, h) were estimated by the model.
Statistical methods
The correlation between dose of S9788 and QTc max was
analysed using general linearmodels with the dose ofS9788 as the
main effect and the patient as the nested effect. The data from 63
cycles in 26 patients were analysed. The difference in non-cardiac
toxicities between treatment with doxorubicin and doxorubicin
plus S9788 was analysed (oc = 0.05) using the two-sided chi-square
and the Fisher's exact tests.
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Table 1 Dose escalation schedule of S9788
Dose level of 2-h infusion
of S9788 (mg m-2) Patients (n) Total number of cycles
24 4 12
48 6 13
72 9 29
96 10 26
120 5 9
Total 34 89
All patients received a loading dose of S9788 at 56 mg m-2 i.v. in 30 min and
doxorubicin at 50 mg m-2 i.v. in 5 min prior to the 2-h infusion of S9788.
RESULTS
Patients characteristics
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A total of 39 patients were entered into the study in eight partici-
pating institutions. One patient was considered ineligible because
of pretreatment with doxorubicin at a cumulative dose of
490 mg m-2 and a previous second malignancy. The number of
assessable patients was therefore 38: 27 patients with colorectal
cancer and 11 with renal cell cancer. The median age was 61 years
(range 34-74) and median Karnofsky performance score was 90%
(range 80-100%). The 28 patients pretreated with chemotherapy
had received a median of two (1-3) regimens. The majority of
these patients had received a 5-fluorouracil-containing regimen for
colorectal cancer. Six of eleven patients with renal cell cancer had
received prior immunotherapy.
Treatment
Sixteen patients started treatment with doxorubicin alone at
50 mg m-2 and received a median of two (1-5) cycles. Of these,
12 patients later received combined treatment with S9788 plus
doxorubicin. The reasons that four patients did not receive the
combined treatment were death due to progressive disease (1),
multiple ventricular extrasystoles during doxorubicin treatment
(1), patient refusal (1) and loss to follow-up (1). The remaining 22
patients started treatment with the combination of S9788 with
doxorubicin.
The number ofpatients treated at the different dose levels ofthe
2-h infusion of S9788 is shown in Table 1. A total of 34 patients
received a median of two cycles (1-8) ofS9788. The planned dose
for both drugs was respected in all patients but one, in whom the
doxorubicin dose was reduced because of grade 3 stomatitis and
grade 4 leucocytopenia. Although the clinical end point of the
study was not reached, the study was terminated because of the
occurrence of a torsade de pointe with syncope in a patient treated
in another French phase I study at a S9788 dose that was lower
than the doses that were used in our study (Terret et al, 1996).
Cardiac toxicity
No major haemodynamic changes occurred in any patient during
the study. No variation > 10% in the ventricular ejection fraction
value was observed within individual patients. A total of 87 Holter
registrations (73 of 24-h and 14 of 48-h) were obtained from 26
patients. On 19 Holter recordings of seven patients during admin-
istration of doxorubicin alone, no arrhythmias or prolongation of
Figure 1. Correlation between QTc max values and S9788 dose levels of
24mg m-2 (n = 4), 48mg m-2 (n = 12), 72mgM-2 (n = 19), 96mgm-2
(n = 22), and 120 mg m-2 (n = 6). S9788 at these dosages was administered
as a 2-h infusion after a loading dose of S9788 at 56 mg m-2 in 30 min
followed by doxorubicin bolus infusion at 50 mg m-2. The correlation was
significant with r= 0.38, P= 0.001 (general linear models)
QTc max > 440 ms were observed. Asymptomatic arrhythmias,
occurring after the start ofS9788 infusion and disappearing within
18 h, were demonstrated on 21 out of 68 Holter recordings of
13 out of 34 patients receiving doxorubicin plus S9788. The
following arrhythmias (frequency of occurrence) were seen:
Mobitz type I (1), Mobitz type II (1), third-degree atrioventricular
block (2), non-sustained ventricular tachycardia (3), supraventric-
ular (8) and ventricular (4) extrasystoles, supraventricular tachy-
cardias of less than 30 s duration (6). These arrhythmias occurred
at all dose levels ofS9788 and were not consistently present during
every cycle in individual patients. In patients receiving doxoru-
bicin plus S9788, the QTc max was < 440 ms in one patient, > 440
and < 600 ms in 20 patients, and > 600 ms in five patients, with a
median value of 541 ms (range 404-685). QTc max occurred
within 3 h after the start of S9788 infusion in 7 out of 26 patients,
between 3 and 6 h in 16 out of26 patients, and after 6 h in 3 out of
26 patients. There was a statistically significant corrrelation
between the QTc max and the dose level of S9788
(r = 0.38, P = 0.001, Figure 1). An increase in the dose ofS9788 of
24 mg m-2 increased the QTc max with an average of 21.5 ms.
There was no correlation between the QTc max and the occurrence
of arrhythmias. No cumulative effect of S9788 on the QTc max
was seen, but a cumulative effect on the occurrence of arrythmias
could not be excluded.
Non-cardiac toxicity
These consisted of alopecia, nausea, vomiting, stomatitis, and
myelosuppression, as might be expected from treatment with
doxorubicin. Compared with treatment with doxorubicin alone,
treatment with the combination of doxorubicin plus S9788 caused
a significant increase in the number ofpatients experiencing WHO
grade 3-4 granulocytopenia (Table 2). No episode of febrile
neutropenia occurred in any patient. A cumulative effect of
doxorubicin as a cause for this toxicity was unlikely, as the first
appearance of grade 3-4 granulocytopenia occurred during the
British Journal ofCancer (1997) 76(10), 1376-1381
6 10 96 120
ann jWJ i
700T
0 CancerResearch Campaign 1997Phase I study ofS9788anddoxorubicin 1379
Table 2 Non-cardiac toxicities
Toxicities WHO grade Doxorubicin Doxorubicin plus S9788 P-valueoveralVgrade 3-4
Nausea 0 10 (62%) 10 (29%)
1/2 6 (38%) 24 (71%)
3/4 0 0 0.06/1.0
Vomiting 0 12 (80%) 17 (50%)
1/2 2 (13%) 14 (41%)
3/4 1 (7%) 3 (9%) 0.13/1.0
Stomatitis 0 16 (100%) 28 (82%)
1/2 0 3 (9%)
3/4 0 3 (9%) 0.20/0.61
Anaemia 0 12 (75%) 14 (47%)
1/2 4 (25%) 13 (43%)
3/4 0 3 (10%) 0.10/0.53
Leucopenia 0 4 (25%) 4 (14%)
1/2 10 (62%) 13 (45%)
3/4 2 (13%) 12 (41%) 0.09/0.09
Granulocytopenia 0 5 (31%) 6 (22%)
1/2 8 (50%) 6 (22%)
3/4 3 (19%) 15 (56%) 0.05/0.04
Thrombocytopenia 0 15 (94%) 33 (97%)
1/2 1 (6%) 0
3/4 0 1 (3%) 0.27/1.0
The incidence of overall toxicity (three categories: grade 0, grade 1-2, grade 3-4) and of grade 3-4 toxicity in patients treated
with doxorubicin vs doxorubicin plus S9788 was analysed two-sided (a = 0.05) with the chi-square test (overall toxicity) and the
exact test (grade 3-4 toxicity). A significant difference was noted in the incidence of grade 3-4 leucocytopenia and
granulocytopenia. Numbers are patients.
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Figure 2. S9788 plasma concentration profile of a patient receiving S9788
at a 30 min loading dose of 56 mg m-2 followed by a 5-min bolus infusion of
doxorubicin and a S9788 2-h maintenance dose of 72 mg m-2. x-axis, time
from start infusion of loading dose of S9788; yaxis, S9788 concentration (gM)
first cycle ofdoxorubicin plus S9788 in 76% ofpatients, and 5 out
of 12 patients with grade 3-4 leucocytopenia and 8 out of 15
patients with grade 3-4 granulocytopenia were not initially treated
with cycles of doxorubicin alone. No statistically significant
differences were found between treatment with doxorubicin and
with doxorubicin plus S9788 when overall toxicity was observed
(Table 2). When the incidence of toxicity was compared with the
number of cycles with and without S9788, a statistically signifi-
cant increase was also found in the incidence of nausea (grade
1-2) and vomiting (grade 1-3) in cycles with doxorubicin plus
S9788. Nausea increased from an incidence of 6 out of 38 of
cycles with doxorubicin alone (16%) to 43 out of89 ofcycles with
doxorubicin plus S9788 (48%) (P = 0.001), and vomiting from 3
out of38 cycles (8%) to 30 out of89 cycles (34%) (P = 0.005). No
significant differences occurred in the incidence or grade of
diarrhoea, hepatic orrenal toxicity (data not shown).
S9788 pharmacokinetics
A total of eight patients were included in the pharmacokinetic
study. All these patients received a loading dose of S9788 of
56 mg m-2 followed by doxorubicin infusion. Thereafter, three
patients received a 2-h infusion ofS9788 at 24 mg m-2, one patient
at 48 mg m-2, two patients at 72 mg m-2 and two patients at
96 mg m-2. A typical plasma concentration profile of S9788 over
time is presented in Figure 2. The mean ± standard deviation (s.d.)
of the maximum plasma concentration reached at the end of the
56 mg m-2 loading dose was 1.31 ± 0.41 gM (range 0.73-2.00).
The maximum values for S9788 concentration during the 2-h
maintenance infusion increased with the administration dose
from 0.38 ± 0.11 ,UM up to 1.05 ± 0.50gM for 24 and 96 mg m-2
respectively. The mean ± s.d. pharmacokinetic parameters were
as follows: CI =47+ 181 h-', Vdss = 669± 2471, t/2a = 7± 5 min,
t'/2j 14± 10 h.
Clinical response
Of the 34 patients who received doxorubicin plus S9788, 29 were
evaluable for response. Ofthese, onepatient with colorectal cancer
had a partial response of 6 months' duration after disease progres-
sion on two cycles of doxorubicin alone. Three patients (one
colorectal and two renal cell cancer) treated with doxorubicin plus
S9788 had stable disease for 3, 4 and 7 months respectively. The
remaining 25 patients had progressive disease.
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DISCUSSION
Clinical studies with MDR-modulating agents have shown disap-
pointing results so far, mainly because of toxicities occurring at
doses that were needed to achieve relevant plasma concentrations
ofthe MDR modulator. Effective MDR reversal by S9788 in vitro
has been observed, beginning at concentrations of 0.25 gM
(Soudon et al, 1995). Therefore, this study shows that, using this
schedule, effective concentrations ofS9788 can be reached at non-
toxic doses in patients. The high total body clearance and short
initial half-life of S9788 that we found support the rationale for
prolonged infusion overbolus infusion ofS9788, as was suggested
by others (Perez et al, 1993; Julia et al, 1994; Soudon et al, 1995).
Compared with treatment with doxorubicin alone, patients treated
with doxorubicin plus S9788 experienced a significant increase in
the occurrence ofWHO grade 3-4 granulocytopenia, but not in the
occurrence or severity of other toxicities. When toxicities were
compared on a per cycle basis, there was also an increase in the
occurrence ofnausea andvomiting. A cumulative effectofdoxoru-
bicin is unlikely as these toxicities mainly occurred during the first
cycle of doxorubicin plus S9788, and occurred equally in patients
initially treated with and without cycles of doxorubicin without
S9788. A pharmacokinetic interaction between S9788 and doxoru-
bicin, as has been shown for instance for verapamil and epirubicin
(Scheithauer et al, 1993) and cyclosporine and doxorubicin
(Bartlett et al, 1994), can be excluded as the interference ofS9788
with the pharmacokinetics ofdoxorubicin has been investigated by
the intra-individual comparisons of the pharmacokinetics parame-
ters ofdoxorubicin obtained during two different cycles ofdoxoru-
bicin treatment without or with S9788 administration (de Valeriola
et al, 1997). In this study, S9788 was not shown to
interfere with doxorubicin pharmacokinetics.
The most common doxorubicin-induced cardiotoxicity is a
cumulative dose-related myocardial cell damage that may result in
congestive heart failure. Acute electrocardiographical changes
and/or arrhythmias during and shortly after administration have
also been described and consistprimarily ofreversible non-specific
ST-T segment changes, sinus tachycardia, premature atrial and
ventricular contractions, and decrease in voltage (Tokaz and Von
Hoff, 1984). The incidence ofthese abnormalities ranges from 0 to
41%. Prolongation ofthe QTc interval associated with arrhythmias
has been described during anthracycline therapy in children and
occurred more frequently in patients who received high cumulative
doses (Bender et al, 1984; Schwartz et al, 1993). In this study, we
found no electrocardiographical changes or arrhythmias in patients
treated with doxorubicin alone, except for one patient who
experienced multiple ventricular extrasystoles. However, in the 26
patients ofwhomHolterrecordings were available during treatment
with the combination of doxorubicin and S9788, a prolongation of
QTc max and cardiac arrhythmias occurred in 25 out of 26 and 13
out of 26 patients respectively. Although it has been demonstrated
that Holter recordings of healthy subjects show arrhythmias in a
significant percentage (Stinson et al, 1995), a causal relationship
between S9788 and these arrythmias seemed probable as they
occurred after the start of S9788 infusion and disappeared within
18 h. A correlation was established between the dose of S9788 and
the prolongation of QTc max, although there was a high variation
between individuals. There was no correlation between the dose of
S9788 and the occurrence of arrhythmias. However, it should be
noted that this study did nothave the appropriate design to establish
these correlations for the following reasons: QTc max is known to
vary between and within individuals, and the QTc dispersion (i.e.
the distribution of repolarization on the heart) rather than the
absolute value of QTc max may be considered as a risk factor for
the occurrence of arrhythmias (Surawicz and Knoebel, 1984).
Moreover, in our study patients were not randomized for the
different S9788 dose levels. In contrast, Terret et al (1996) found
no correlation between QTc lengthening and dose of S9788 in
other phase I studies. This might be explained by the above-
mentioned reasons, and/or by the fact that other doses and
schedules ofS9788 were used. Although apredictive value ofQTc
lengthening for the occurrence of severe arrhythmias has never
been established for values < 600 ms (Surawicz and Knoebel,
1984), the study was terminated after the occurrence of severe
cardiac arrhythmias (torsade de pointe with syncope) in another
ongoing study with S9788 given over 6 h (Terret et al, 1996). Such
a risk would preclude the routine use ofS9788.
The clinical activity of treatment with doxorubicin plus S9788
was limited to one partial response in a patient with colorectal
cancer, but a causative role of S9788 was obvious as this patient
had disease progression during prior treatment with doxorubicin
alone. It should be noted that a suboptimal dose of doxorubicin
was chosen for safety reasons.
In conclusion, we have safely administered a combination treat-
ment of doxorubicin and S9788 to 39 patients, and with the doses
used relevant concentrations of S9788 were achieved. However,
because of the unpredictable occurrence of cardiac arrhythmias,
the company has decided to withdraw the drug S9788 from further
clinical development.
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